Gilead Defends Growth Prospects As Veklury Sales Drive Q3 Revenue Surge

Guidance Lowered For Sales Excluding The COVID-19 Drug

 
• By Mandy Jackson
  
Gilead sign at their headquarters in Foster City
Gilead expects up to $26.3bn in 2021 product sales, $21.5bn excluding Veklury • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business